Delving into the Latest Updates on RD-133 with Synapse

This study is a single-center exploratory clinical trial. It is estimated that 9-24 subjects will be enrolled. The "3+3" dose escalation design is adopted. The main purpose is to evaluate the safety of RD133 in the treatment of subjects with relapsed or refractory MSLN-positive solid tumors and explore the Recommend phase II dose of RD133 in the treatment of patients with relapsed/refractory MSLN-positive solid tumors.

Start Date12 Jan 2022

Sponsor / Collaborator

Shanghai Tongji Hospital

[+1]

NCT05166070 / RecruitingEarly Phase 1IIT

An Exploratory Clinical Study to Evaluate the Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors

This study is a single-center exploratory clinical trial. It is estimated that 9-24 subjects will be enrolled. The "3+3" dose escalation design is adopted. The main purpose is to evaluate the safety of RD133 in the treatment of subjects with relapsed or refractory MSLN-positive solid tumors and explore the Recommend phase II dose of RD133 in the treatment of patients with relapsed/refractory MSLN-positive solid tumors.

Start Date01 Jan 2022

Sponsor / Collaborator

Third Affiliated Hospital of Nanjing Medical University

[+1]

100 Clinical Results associated with RD-133

Login to view more data

100 Translational Medicine associated with RD-133

Login to view more data

100 Patents (Medical) associated with RD-133

Login to view more data

100 Deals associated with RD-133

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Mesothelin positive Solid Tumors	Phase 1	CN	Shanghai IASO Biotherapeutics Co., Ltd.	01 Jan 2022
Solid tumor	Discovery	CN	Nanjing IASO Biotherapeutics Co., Ltd.Startup	09 Sep 2021